These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 30715618)

  • 21. Targeting Wnts at the source--new mechanisms, new biomarkers, new drugs.
    Madan B; Virshup DM
    Mol Cancer Ther; 2015 May; 14(5):1087-94. PubMed ID: 25901018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Developing drugs that target the Wnt pathway: recent approaches in cancer and neurodegenerative diseases.
    Serafino A; Sferrazza G; Colini Baldeschi A; Nicotera G; Andreola F; Pittaluga E; Pierimarchi P
    Expert Opin Drug Discov; 2017 Feb; 12(2):169-186. PubMed ID: 27960558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Wnt/beta-catenin signaling pathway as a novel cancer drug target.
    Luu HH; Zhang R; Haydon RC; Rayburn E; Kang Q; Si W; Park JK; Wang H; Peng Y; Jiang W; He TC
    Curr Cancer Drug Targets; 2004 Dec; 4(8):653-71. PubMed ID: 15578921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
    Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
    J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Wnt signaling in cancer.
    Zhan T; Rindtorff N; Boutros M
    Oncogene; 2017 Mar; 36(11):1461-1473. PubMed ID: 27617575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
    Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E
    Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the wingless signaling pathway with natural compounds as chemopreventive or chemotherapeutic agents.
    Teiten MH; Gaascht F; Dicato M; Diederich M
    Curr Pharm Biotechnol; 2012 Jan; 13(1):245-54. PubMed ID: 21466435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer.
    Cheng X; Xu X; Chen D; Zhao F; Wang W
    Biomed Pharmacother; 2019 Feb; 110():473-481. PubMed ID: 30530050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of small molecule inhibitors of the Wnt/β-catenin signaling pathway by targeting β-catenin/Tcf4 interactions.
    Yan M; Li G; An J
    Exp Biol Med (Maywood); 2017 Jun; 242(11):1185-1197. PubMed ID: 28474989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antagonizing canonical Wnt signaling pathway by recombinant human sFRP4 purified from E. coli and its implications in cancer therapy.
    Ghoshal A; Ghosh SS
    Mol Cell Biochem; 2016 Jul; 418(1-2):119-35. PubMed ID: 27334754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is β-Catenin a Druggable Target for Cancer Therapy?
    Cui C; Zhou X; Zhang W; Qu Y; Ke X
    Trends Biochem Sci; 2018 Aug; 43(8):623-634. PubMed ID: 30056837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisleuconothine A, a bisindole alkaloid, inhibits colorectal cancer cell in vitro and in vivo targeting Wnt signaling.
    Kong LM; Feng T; Wang YY; Li XY; Ye ZN; An T; Qing C; Luo XD; Li Y
    Oncotarget; 2016 Mar; 7(9):10203-14. PubMed ID: 26862734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Notch and Wnt signaling pathway in cancer: Crucial role and potential therapeutic targets (Review).
    Xiao YF; Yong X; Tang B; Qin Y; Zhang JW; Zhang D; Xie R; Yang SM
    Int J Oncol; 2016 Feb; 48(2):437-49. PubMed ID: 26648421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
    Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
    Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Tankyrase to Fight WNT-dependent Tumours.
    Thorvaldsen TE
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):81-88. PubMed ID: 28371398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of Small Molecules Targeting the Wnt Signaling Pathway in Cancer Stem Cells for the Treatment of Colorectal Cancer.
    Song L; Li Y; He B; Gong Y
    Clin Colorectal Cancer; 2015 Sep; 14(3):133-45. PubMed ID: 25799881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Wnt signaling pathway in cancer.
    Duchartre Y; Kim YM; Kahn M
    Crit Rev Oncol Hematol; 2016 Mar; 99():141-9. PubMed ID: 26775730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential of targeting Wnt/β-catenin in colon cancer.
    Sebio A; Kahn M; Lenz HJ
    Expert Opin Ther Targets; 2014 Jun; 18(6):611-5. PubMed ID: 24702624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mining the Wnt pathway for cancer therapeutics.
    Barker N; Clevers H
    Nat Rev Drug Discov; 2006 Dec; 5(12):997-1014. PubMed ID: 17139285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting.
    Hankey W; Frankel WL; Groden J
    Cancer Metastasis Rev; 2018 Mar; 37(1):159-172. PubMed ID: 29318445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.